Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with ...
...We conducted a multicenter, double-blind, phase 3, randomized, active-controlled noninferiority trial to evaluate the efficacy and safety of benralizumab as compared with mepolizumab....
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2311155
MANDARA Phase III data published in New England Journal of Medicine ...
...This is a significant advancement and show that benralizumab helped patients achieve remission and reduce chronic OCS usage, in a convenient, single, monthly subcutaneous injection, and could alleviate some of the impact of this debilitating disease.?...
https://www.astrazeneca.com/media-centre/medical-releases/mandara-phase-iii-data-published-new-england-journal-medicine-show-remission-achievable-goal-eosinophilic-granulomatosis-polyangiitis-egpa-fasenra.html
Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab ...
...A Randomised, Double-blind, Active-controlled 52-week Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy (MANDARA Study)...
https://clinicaltrials.gov/study/NCT04157348
Benralizumab noninferior to mepolizumab for EGPA - Nature
...Now, the results of the phase III MANDARA trial demonstrate that benralizumab, a monoclonal antibody that targets the IL-5? receptor expressed on eosinophils, is noninferior to......
https://www.nature.com/articles/s41584-024-01116-6
MANDARA: Benralizumab Proves Noninferiority to Mepolizumab for EGPA
...The MANDARA trial results, published in NEJM, show benralizumab's noninferiority to mepolizumab in eosinophilic granulomatosis with polyangiitis, with potential for oral glucocorticoid discontinuation....
https://www.hcplive.com/view/mandara-benralizumab-proves-noninferiority-to-mepolizumab-for-egpa
Efficacy and Safety of Benralizumab Compared with Mepolizumab in the ...
...MANDARA compared efficacy and safety of benralizumab and mepolizumab in patients with eosinophilic granulomatosis with polyangiitis (EGPA) receiving standard of care. MANDARA was a multicenter, randomized, double-blind, 52-week, Phase III, non-inferiority study (NCT04157348)....
https://www.jacionline.org/article/S0091-6749(23)02359-X/fulltext
MANDARA Phase III data published in the NEJM show remission is an ...
...MANDARA was a randomised, double blind, double-dummy, active-controlled, parallel group, multicentre 52-week Phase III trial which compared the efficacy and safety of Fasenra to mepolizumab in adult patients with relapsing or refractory EGPA....
https://checkorphan.org/news/mandara-phase-iii-data-published-in-the-nejm-show-remission-is-an-achievable-goal-in-eosinophilic-granulomatosis-with-polyangiitis-egpa-with-fasenra/
EGPA Clinical Trials Data with MANDARA Study - FASENRA (benralizumab)
...MANDARA (52 weeks) is a Phase 3, multicenter, double-blind, randomized, active-controlled, head-to-head, noninferiority trial evaluating the efficacy and safety of FASENRA 30 mg SC compared to mepolizumab 300 mg SC every 4 weeks....
https://www.fasenrastudies.com/egpa/clinical-data
Mepolizumab versus benralizumab for eosinophilic granulomatosis with ...
...Following the results of the MANDARA trial, this real-life study aimed at comparing the effectiveness and safety profile of mepolizumab versus benralizumab in a European EGPA cohort....
https://www.sciencedirect.com/science/article/pii/S0896841125000435
Fasenra recommended for approval in the EU by CHMP for the treatment of ...
...MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with Fasenra....
https://www.astrazeneca.com/media-centre/press-releases/2024/fasenra-recommended-for-eu-approval-in-egpa.html
FASENRA Achieves Remission in EGPA, According to NEJM ... - Patsnap
...The trial showed that benralizumab not only met its primary endpoint but also exhibited non-inferior rates of remission when compared to mepolizumab. A noteworthy 59% of benralizumab-treated patients were in remission at weeks 36 and 48, closely followed by 56% of mepolizumab-treated patients....
https://synapse.patsnap.com/article/fasenra-achieves-remission-in-egpa-according-to-nejm-published-mandara-trial